These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
819 related articles for article (PubMed ID: 32571374)
1. cGAS-STING, an important pathway in cancer immunotherapy. Jiang M; Chen P; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; Ye L; He Y; Zhou C J Hematol Oncol; 2020 Jun; 13(1):81. PubMed ID: 32571374 [TBL] [Abstract][Full Text] [Related]
2. Engineering and Delivery of cGAS-STING Immunomodulators for the Immunotherapy of Cancer and Autoimmune Diseases. Zhou S; Cheng F; Zhang Y; Su T; Zhu G Acc Chem Res; 2023 Nov; 56(21):2933-2943. PubMed ID: 37802125 [TBL] [Abstract][Full Text] [Related]
3. cGAS-STING signaling in cancer immunity and immunotherapy. Du H; Xu T; Cui M Biomed Pharmacother; 2021 Jan; 133():110972. PubMed ID: 33254021 [TBL] [Abstract][Full Text] [Related]
4. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553 [TBL] [Abstract][Full Text] [Related]
5. Agonists and Inhibitors of the cGAS-STING Pathway. Yu X; Cai L; Yao J; Li C; Wang X Molecules; 2024 Jun; 29(13):. PubMed ID: 38999073 [TBL] [Abstract][Full Text] [Related]
6. Intrinsic strategies for the evasion of cGAS-STING signaling-mediated immune surveillance in human cancer: How therapy can overcome them. Zou SS; Qiao Y; Zhu S; Gao B; Yang N; Liu YJ; Chen J Pharmacol Res; 2021 Apr; 166():105514. PubMed ID: 33631336 [TBL] [Abstract][Full Text] [Related]
7. Metal coordination nanotheranostics mediated by nucleoside metabolic inhibitors potentiate STING pathway activation for cancer metalloimmunotherapy. Yang L; Wang Y; Song Y; Li Z; Lei L; Li H; He B; Cao J; Gao H J Control Release; 2024 Jun; 370():354-366. PubMed ID: 38685387 [TBL] [Abstract][Full Text] [Related]
8. STING-mediated DNA sensing in cancer immunotherapy. Zhou X; Jiang Z Sci China Life Sci; 2017 Jun; 60(6):563-574. PubMed ID: 28639100 [TBL] [Abstract][Full Text] [Related]
9. A DNA-Modularized STING Agonist with Macrophage-Selectivity and Programmability for Enhanced Anti-Tumor Immunotherapy. Chen Y; Li R; Duan Q; Wu L; Li X; Luo A; Zhang Y; Zhao N; Cui K; Wu W; Liu T; Wan JB; Deng L; Li G; Hou L; Tan W; Xiao Z Adv Sci (Weinh); 2024 Aug; 11(32):e2400149. PubMed ID: 38898748 [TBL] [Abstract][Full Text] [Related]
10. Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects. Wang B; Yu W; Jiang H; Meng X; Tang D; Liu D Front Immunol; 2024; 15():1485546. PubMed ID: 39421752 [TBL] [Abstract][Full Text] [Related]
11. The cGAS/STING Pathway: A Novel Target for Cancer Therapy. Gan Y; Li X; Han S; Liang Q; Ma X; Rong P; Wang W; Li W Front Immunol; 2021; 12():795401. PubMed ID: 35046953 [TBL] [Abstract][Full Text] [Related]
12. Insight into the dichotomous regulation of STING activation in immunotherapy. Hu Z; Yang Y; Fang L; Zhou J; Zhang H Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):126-137. PubMed ID: 33618600 [TBL] [Abstract][Full Text] [Related]
13. Triggering of the cGAS-STING Pathway in Human Plasmacytoid Dendritic Cells Inhibits TLR9-Mediated IFN Production. Deb P; Dai J; Singh S; Kalyoussef E; Fitzgerald-Bocarsly P J Immunol; 2020 Jul; 205(1):223-236. PubMed ID: 32471881 [TBL] [Abstract][Full Text] [Related]
14. cGAS/STING cross-talks with cell cycle and potentiates cancer immunotherapy. Long ZJ; Wang JD; Xu JQ; Lei XX; Liu Q Mol Ther; 2022 Mar; 30(3):1006-1017. PubMed ID: 35121107 [TBL] [Abstract][Full Text] [Related]
15. Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies. Zhang J; Yu S; Peng Q; Wang P; Fang L Cancer Biol Med; 2024 Jan; 21(1):45-64. PubMed ID: 38172538 [TBL] [Abstract][Full Text] [Related]
16. A General Biomineralization Strategy to Synthesize Autologous Cancer Vaccines with cGAS-STING Activating Capacity for Postsurgical Immunotherapy. Li Q; Dong Z; Cao Z; Lei H; Wang C; Hao Y; Feng L; Liu Z ACS Nano; 2023 Jun; 17(11):10496-10510. PubMed ID: 37184402 [TBL] [Abstract][Full Text] [Related]
17. Intratumoral delivery of the chitin-derived C100 adjuvant promotes robust STING, IFNAR, and CD8 Turley JL; Ward RW; Huete-Carrasco J; Muñoz-Wolf N; Roche K; Jin L; Bowie A; Andersson M; Lavelle EC Cell Rep Med; 2024 May; 5(5):101560. PubMed ID: 38729159 [TBL] [Abstract][Full Text] [Related]
18. STING Activation and its Application in Immuno-Oncology. Lian Y; Duffy KJ; Yang J Curr Top Med Chem; 2019; 19(24):2205-2227. PubMed ID: 31642767 [TBL] [Abstract][Full Text] [Related]
19. Targeting STING for cancer immunotherapy: From mechanisms to translation. Huang R; Ning Q; Zhao J; Zhao X; Zeng L; Yi Y; Tang S Int Immunopharmacol; 2022 Dec; 113(Pt A):109304. PubMed ID: 36252492 [TBL] [Abstract][Full Text] [Related]
20. 2',3'-Cyclic GMP-AMP Dinucleotides for STING-Mediated Immune Modulation: Principles, Immunotherapeutic Potential, and Synthesis. Shang M; Lu K; Guan W; Cao S; Ren M; Zhou C ChemMedChem; 2022 Jan; 17(2):e202100671. PubMed ID: 34807508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]